SCHEMBL5578465

SCHEMBL5578465

c1ccc([C]2N=NN=C2c2ccccc2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
RAB9A P51151 4/20 0.35
NPC1 O15118 3/20 0.35
MAPK1 P28482 1/20 0.35
NOTUM Q6P988 1/20 0.33
IDO1 P14902 1/20 0.32
SCN4A P35499 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
ATM Q13315 1/20 0.31
ALOX15 P16050 1/20 0.31
NR1H2 P55055 1/20 0.30
NR1H3 Q13133 1/20 0.30
HTT P42858 1/20 0.30
ADORA2A P29274 1/20 0.30
ADORA1 P30542 1/20 0.30
NFKB1 P19838 1/20 0.30
NFKB2 Q00653 1/20 0.30
RELA Q04206 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8718613 0.76 MAPT (0.39) ALDH1A1RAB9ANPC1MAPK1NOTUM
SCHEMBL10412917 0.71 ALDH1A1 (0.35) ALDH1A1RAB9ANPC1MAPK1MEN1
SCHEMBL15511089 0.70 ALDH1A1 (0.40) ALDH1A1RAB9ANPC1MAPK1NOTUM
SCHEMBL576916 0.66 ALDH1A1 (0.47) ALDH1A1RAB9ANPC1MAPK1NOTUM
SCHEMBL405762 0.60 ALDH1A1 (0.47) ALDH1A1RAB9ANPC1MAPK1NOTUM
SCHEMBL12997586 0.60 ALDH1A1 (0.47) ALDH1A1RAB9ANPC1MAPK1NOTUM
SCHEMBL1326009 0.58
Biphenyl SCHEMBL1358618 0.58 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1MAPK1NOTUM
Biphenyl SCHEMBL4002609 0.58 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1MAPK1NOTUM
Biphenyl SCHEMBL2548048 0.58 ALDH1A1 (1.00) ALDH1A1RAB9ANPC1MAPK1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070021330-A1 Aza-peptide macrocyclic hepatitis c serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2007-01-25 US disclosed
US-7125845-B2 Aza-peptide macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2006-10-24 US disclosed
US-20050065073-A1 Aza-peptide macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. 2005-03-24 US disclosed
WO-2005010029-A1 AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021330-A1 Aza-peptide macrocyclic hepatitis c serine protease inhibitors VIP, CTSC, DPP4 ALDH1A1 2329/4885RAB9A 2489/4885NPC1 323/4885
US-20050065073-A1 Aza-peptide macrocyclic hepatitis C serine protease inhibitors VIP, CTSC, PRSS1 ALDH1A1 2265/4885RAB9A 2515/4885NPC1 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.